Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693
Sponsor: AstraZeneca
Summary
Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
Official title: A Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of AZD2693.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
35
Start Date
2023-06-16
Completion Date
2024-09-16
Last Updated
2026-05-11
Healthy Volunteers
Yes
Conditions
Interventions
AZD2693
Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
Locations (3)
Research Site
Rialto, California, United States
Research Site
Miami Lakes, Florida, United States
Research Site
Orlando, Florida, United States